Global Epigenetics Market Size study & Forecast, by Product (Instruments, Kits and Reagents, Others), by Application (Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases, Cardiovascular Diseases), by Technology (Methylation, Acetylation,

Global Epigenetics Market Size study & Forecast, by Product (Instruments, Kits and Reagents, Others), by Application (Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases, Cardiovascular Diseases), by Technology (Methylation, Acetylation, Phosphorylation, Other Technologies) and Regional Analysis, 2023-2030

Global Epigenetics Market is valued approximately at USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than 16.1% over the forecast period 2023-2030. Epigenetics is the study of gene changes that may affect common gene mutations. Epigenetic mechanisms are being linked to an increasing number of chronic diseases and disorders, including cardiovascular diseases, autoimmune diseases, and neurodegenerative disorders, in addition to environmental factors and nutrition, which affect epigenetic processes such as DNA methylation, histone modification, and non-coding RNA. Innovative therapeutic strategies can now be developed because of the identification of numerous cutting-edge therapeutic targets through epigenetic research. Factors such as rising expenditure in Research and Development, Increasing Cancer cases and increasing uses of non-oncological applications of epigenetics are expected to drive the growth of the epigenetics market in the forecast year 2023-2030.

According to Statista, cancer is one of the biggest health issues in the world that affects millions of people of all ages and genders and has a significant negative influence on quality of life. The incidence of new cancer cases is rising along with the average age of the world's population, which results in more deaths each year. Globally, there were around 10 million cancer-related deaths in 2020; and this number is predicted to rise to over 16 million, by 2040. Rising healthcare research & development expenditure globally is also anticipated to fuel market expansion. According to the World Health Organization in December 2021, the gross domestic research and development expenditure (health GERD) as a percentage of gross domestic product (GDP) in high-income nations was 0.21% and 0.02% for upper middle- and low-income nations. Moreover, the increasing demand in patients’ base for personalized medicine and high use of epigenetics in therapeutics and drug development may create lucrative opportunities for the market in the forecast period. However, the lack of skilled professionals working in this field stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Epigenetics Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share owing to the presence of key market players, significant investments in research and development, and a rise in cancer cases. According to the United States National Institute of Health, USD 1,098 million had been allocated for cancer genomics research as of December 2021, thus driving the growth of the market. However, Asia Pacific is expected to be the fastest growing region during the forecast period, owing to rising awareness in epigenetics, prevalence of key players in developing countries of Asia Pacific, and developing infrastructure for research and clinical settings.

Major market player included in this report are:
Abcam PLC
Illumina Inc.
Bio-Rad Technologies
Hologic Inc (Diagenode Inc.)
Thermo Fisher Scientific
Perkin Elmer
New England Biolabs
Active Motiff
Zymo Research Corporation
Qiagen NV

Recent Developments in the Market:
In December 2022, Merck Announces Mersana Therapeutics Collaboration to Create New Immunostimulatory Antibody-Drug Conjugates.
In August 2022, Merck KGaA, a leading science and technology company, signed a definitive agreement to acquire the chemical division of Mecaro Co. Ltd. (Mecaro), a publicly traded Korean manufacturer of heater blocks and chemical precursors for semiconductors.
In February 2022, Element Biosciences, Inc., the creator of a novel and innovative DNA sequencing technology partnered with Dovetail Genomics to showcase the benefits and effectiveness of Dovetail’s proximity ligation-based next-generation sequencing (NGS) library prep solutions on Element's AVITI System.

Global Epigenetics Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, Application, Technology, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Instruments
Kits and Reagents
Others
By Application:
Oncology
Autoimmune Diseases
Metabolic Diseases
CNS/Pain Diseases
Cardiovascular Diseases
By Technology:
Methylation
Acetylation
Phosphorylation
Other Technologies

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Abcam PLC
Illumina Inc.
Bio-Rad Technologies
Hologic Inc (Diagenode Inc.)
Thermo Fisher Scientific
Perkin Elmer
New England Biolabs
Active Motiff
Zymo Research Corporation
Qiagen NV

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.